Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coenzyme Q10 in NAFLD
NCT05941910Phase 2Unknown
- Sponsor
- Attikon University Hospital
- Start
- Apr 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Coenzyme Q10 mucoadhesive tablets in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Attikon University Hospital. Primary endpoint: Left Ventricular Myocardial Function at 6 months. Status: unknown.
02
Drugs
Coenzyme Q10 mucoadhesive tablets
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05941910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05941910.